Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ: IRON )

63.51 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Disc Medicine, Inc. - Common Stock

< Previous 1 2 Next >
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
From Disc Medicine Inc
Via GlobeNewswire
NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc
San Diego, CA -- (SBWIRE) -- 12/08/2023 -- Certain directors of Disc Medicine Opco Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC) 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Underwritten Offering of Common Stock
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
From Disc Medicine Inc
Via GlobeNewswire
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.